The role of the hospital pharmacist to guarantee access and continuity of care for the management of epilepsy
DOI:
https://doi.org/10.33393/grhta.2023.2970Keywords:
Epilepsy, Deprescribing, Hospital Pharmacists, Management, Multidisciplinary, Novel Drug Distribution, PharmacovigilanceAbstract
In this article the pivotal role of hospital pharmacists in the multidisciplinary management of epilepsy is discussed. Hospital pharmacists are members of national and local ethics committees, oversee clinical trials, and ensure adherence to regulations for patient access to novel therapeutic treatments. They actively contribute to regulatory processes and the definition of prescribing centers. In the post-launch phase, hospital pharmacists are a key member in the multidisciplinary team, they are involved in decisions relating to the local introduction of drugs, in the management of the drug within the hospital structure and with the direct distribution, and to ensure proper and timely treatment. The pharmacovigilance network, including hospital and community pharmacists, monitors and prevents adverse effects related to epilepsy medications and enhances a collaborative approach with specialists to promote prescription appropriateness, targeting therapy for better patient outcomes. Finally, the potential benefits of deprescribing are briefly discussed, underscoring the importance of a multidisciplinary approach involving doctors and clinical pharmacists to gather comprehensive data and enhance patient care in epilepsy management.
Downloads
References
De Vivo G, Magni E, Muserra G, et al. Il farmacista clinico nella gestione dell’epilessia: punto di riferimento per il paziente e punto di forza dei gruppi multidisciplinari. Boll SIFO 2022;68(3):207-213. http://dx.doi.org/10.1704/3851.38350
Monzillo J, Scicchitano F, De Fina M, et al. La medicina di precisione: focus su Epilessia. Boll SIFO 2021;67(6):180-187. http://dx.doi.org/10.1704/3756.37401
Reeve E, Gnjidic D, Long J, Hilmer S. A systematic review of the emerging definition of “deprescribing” with network analysis: implications for future research and clinical practice Br J Clin Pharmacol. 2015 Dec;80(6):1254-1268. https://doi.org/10.1111/bcp.12732. PMID: 27006985 DOI: https://doi.org/10.1111/bcp.12732
Published
How to Cite
Issue
Section
License
Copyright (c) 2023 The authors
![Creative Commons License](http://i.creativecommons.org/l/by-nc/4.0/88x31.png)
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Authors contributing to Global & Regional Health Technology Assessment agree to publish their articles under the CC-BY-NC 4.0 license, which allows third parties to re-use the work without permission as long as the work is properly referenced and the use is non-commercial.